Today, the Television Bureau of Advertising (TVB), the not-for-profit trade association of America’s commercial broadcast television industry, the National Highway Traffic Safety Administration (NHTSA), and the Ad Council launched their 11th year of “Project Roadblock: Local TV Puts the Brakes on Drunk Driving.” Launched in December 2003, Project Roadblock is the local broadcast television industry’s extension of NHTSA and the Ad Council’s ‘Buzzed Driving is Drunk Driving’ PSA campaign. Since then, the multi-media campaign has served as an opportunity for local television stations to combat drunk driving by donating on-air, online and mobile advertising time and space for the PSAs. To date, broadcast TV stations across the nation have donated more than $34 million in media to support this effort.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391951-ad-council-tvb-nhtsa-partner-to-prevent-drunk-driving-fatalities-during-holidays/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
The Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) today announced its first-ever, national advertising campaign aimed at parents of children ages 8-14 to make sure their kids are consistently and properly wearing their seat belt every time the car is moving.
“Buckling up is an important habit to instill in children at a young age. As parents, we need to lead by example and reinforce the message to make sure it sticks,” said U.S. Transportation Secretary Anthony Foxx. “This campaign urges parents to never give up until their kids buckle up.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7467951-psa-kids-seat-belt-safety-ad-council/
New proposed regulations from the Obama administration will force power plants to abandon the use of coal, the largest source of the nation’s electricity, resulting in higher utility bills for households and businesses and lost opportunities for responsibly reducing greenhouse gas emissions, the National Mining Association (NMA) said today.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63063-national-mining-association-nma-epa-new-source-performance-standard
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
http://www.miraclemulti.com MiracleMulti™ The Best Multivitamins on the market for Men, Women, Vegetarians, and Bodybuilding. Once a day Multivitamin for Health, Energy, Focus, Well Being and Anti-aging.***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Money Management International (MMI) is participating in a nationwide partnership to help families struggling with their mortgage payments apply for help from the Federal government’s Making Home Affordable Program (MHA). The MHA program is an important part of the Obama administration’s comprehensive plan to help homeowners get mortgage relief and avoid foreclosure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52440-money-management-international-mmi-mortgage-relief-mha-program
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Spring is around the corner, and it won’t be long before it’s prom and graduation seasons for many high schoolers. Rites of passage for many, these are times for teens to celebrate, but can also be times of poor decision-making, especially when vehicles are involved. The National Highway Traffic Safety Administration (NHTSA) reports that 2,524 teen drivers and passengers were killed and 177,000 were injured in 2013. Twenty-seven percent of these fatalities occurred between April and June, according to the Insurance Institute for Highway Safety (IIHS).
“The statistics are staggering, especially when you consider that most of these accidents and fatalities are preventable,” said Randy Petro, Mercury Insurance’s chief claims officer. “We don’t want any families to suffer through the loss of a child, so Mercury is taking action with the launch of the ‘Mercury Insurance Drive Safe Challenge.’”
The Mercury Insurance Drive Safe Challenge kicked off with a free defensive driving program, which included hands-on driving skills training and classroom material. An interactive website provides teens with detailed instruction, as well as gives parents the tools to shape responsible driving behavior.
To view the multimedia release go to:
http://www.multivu.com/players/English/7772251-mercury-teen-drive-safe-challenge/
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
